

## Parvovirus Spreading Rapidly Among Dogs, Veterinarians Warn of Severe Outbreak<sup>1</sup>

July 22<sup>nd</sup> 2021

There has been an increase in the number of parvovirus cases among pet dogs in India & experts have warned that this can lead to a severe outbreak. At a time when the country is fighting its biggest battle against ferocious coronavirus in its second wave, cases of a new virus spreading rapidly among the furry animals are on the rise - Parvovirus. According to the veterinarians, dogs who are less than a year old are more at risk, since their immunity is low as compared to the dogs of other ages. Speaking to the media, a Chennai-based veterinarian said, "The number of dogs with parvovirus infection has gone up in the past month due to weather changes, lack of vaccination & low immunity system." He further added that the infected dogs should be taken to the hospital immediately after developing symptoms.

## Fluid therapy: twice maintenance just isn't good enough<sup>2</sup>

Vetpol, July 2021

Fluid therapy is a topic that sometimes gets overlooked by vets, partly because there is a misconception that developing fluid plans can be difficult. However, if you keep it simple, you can develop a tailored fluid therapy plan for your patient that is much better than a blanket "twice maintenance" rate. There are four basic components to a fluid therapy plan that you need to think about: Perfusion deficit, Hydration deficit, Maintenance requirements, Ongoing losses. So, when taking these four components of a fluid therapy plan into account, you'll soon see that, frequently, twice maintenance is not enough. The final and most important part of every fluid therapy plan is reassessment. Reassess your patient every couple hours to determine if your plan is appropriate and adjust accordingly.

## FDA grants first full approval for treatment of lymphoma in dogs<sup>3</sup>

FDA, July 15<sup>th</sup> 2021

U.S. Food and Drug Administration fully approved Tanovea (Rabacfosadine injection) to treat lymphoma in dogs. Tanovea is the first conditionally approved new animal drug for dogs to achieve the FDA's full approval. The effectiveness & safety of Tanovea was demonstrated in a well-controlled clinical field study involving a total of 158 dogs that had been diagnosed with multicentric lymphoma with at least one enlarged peripheral lymph node. The study found that Tanovea extended the median survival rate by 61 days & for dogs with a complete response to the drug, the median progression-free survival was extended to 168 days.

## MARKET RESEARCH



### CONDITIONS FOR WHICH PET SUPPLEMENTS ARE PURCHASED, 2020

(% of pet supplement purchasers)

Joint/mobility.....	30%
Skin/coat.....	29%
General health/multivitamins.....	29%
Immune system health.....	27%
Stress/anxiety/calming.....	23%
Heart health.....	23%
Dental/oral health.....	23%
Probiotic.....	22%
Digestive health/nausea.....	20%
Allergy relief.....	20%

Source : Packaged facts

## STUDY

### Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease

Viruses, April 2021

The pharmacological effects of the primary active compound of the licorice root, glycyrrhizin include anti oxidative & anti-inflammatory activities. Glycyrrhizin was discussed in in-silico simulations as a potential protease inhibitor. Beside the viral main protease (Mpro), the transmembrane serine protease (TMPRSS2) is another discussed target of glycyrrhizin. TMPRSS2 was shown to cleave the SARS-CoV-2 spike protein thereby facilitating the entry of the virus into the host cell. However, since there was only a slight difference in antiviral activity of glycyrrhizin between pre- & post-entry conditions & only a minor affinity was simulated for the interaction between glycyrrhizin & TMPRSS2 in former in silico studies, we concluded that glycyrrhizin blocks SARS-CoV-2 replication mainly via a mechanism different from inhibiting TMPRSS2. Thus, we focused on the SARS-CoV-2 main protease (Mpro) as a potential target for glycyrrhizin. Mpro is essential for processing the viral polyproteins that are translated from the viral RNA & thus, for virus replication. Therefore, the inhibition of the SARS-CoV-2 main protease would inhibit the viral replication. Taken together, we demonstrated that **glycyrrhizin, the primary active ingredient of the licorice root, potentially blocks SARS-CoV-2 replication by inhibiting the viral main protease.**

# VIUSID

For Immunity & Viral Infections



**Immunobooster**  
**Powerful antioxidant**  
**Antiviral**

**Presentation:**  
150 ml, 30 ml

**Dose:**  
1ml/5kg body weight every 12 hrs

Stay connected with

[facebook.com/vivaldisanimalhealth](https://www.facebook.com/vivaldisanimalhealth) | [instagram.com/vivaldisanimalhealth](https://www.instagram.com/vivaldisanimalhealth) | [linkedin.com/company/vivaldisanimalhealth](https://www.linkedin.com/company/vivaldisanimalhealth)